U.S. FDA to Phase Out Animal Testing for the Development of Monoclonal Antibodies and Other Drugs
The FDA’s animal testing requirement will be decreased, modified, or potentially replaced utilizing a variety of methodologies.
Category: News
Newly Developed Gene Editing Tool Shows Promising Results for Treating Diseases with Multiple Mutations
By inserting a complete gene, the technique provides a one-step solution that overcomes the limitations of CRISPR gene editing technology.
Dire Wolf Returns After 12000 Years By De-Extinction Technology
Colossal Biosciences, the business seeking to make extinction optional, has resurrected a prehistoric predator best known for its role in Game of Thrones. Approximately 20 [Read More…]
mAb Capture Made Cost Effective and Productive With Cytiva’s Protein A Resins
A one-size-fits-all strategy to protein purification is no longer practicable, given the development and transformation of the mAb market, notably the recent rapid emergence of [Read More…]
Ozempic® Results from STRIDE Shown to Improve Walking Distance and Quality of Life in Adults With Type 2 Diabetes and Peripheral Artery Disease (PAD)
Novo Nordisk presented the full results of STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial that looked at the effects of once-weekly injectable Ozempic®.
U.S. FDA Approved Amgen’s UPLIZNA® (INEBILIZUMAB-CDON) for the Treatment of Rare Immune Disorder
IgG4-RD can arise in various organs, causing fibrosis and irreversible organ damage. Understanding how organ damage occurs is key to making an accurate diagnosis of IgG4-RD.
Aldeyra Therapeutics Responds to the U.S. FDA’s Denial of Reproxalap’s NDA Application for Treating Signs and Symptoms of Dry Eye Disease
FDA stated in the letter that the NDA “failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes”.
Pfizer’s RSV Lower Respiratory Tract Disease Vaccine ABRYSVO®Approved by European Commission
Pfizer Inc (PFI). announced that the European Commission (EC) has amended the marketing authorization for ABRYSVO®, the company’s bivalent respiratory syncytial virus (RSV) prefusion F [Read More…]
Abbott’s Voltâ„¢ Pulsed Field Ablation System Receives CE Mark to Treat Patients with Abnormal Heart Rhythms
AFib affects around 8 million Europeans over the age of 65, and this figure is anticipated to grow over the next 30 years.
U.S. FDA Approved Sanofi’s Qfitlia to Treat Hemophilia
In order to help hemophiliacs regain hemostasis, Qfitlia helps boost thrombin production by decreasing AT, a protein that prevents blood clotting.
